Business Impact of the COVID-19 Pandemic
First written in FY2020. 6 of 12 entries say "Restated". Latest entry: FY2024.
The whole theme swung hardest in 2022: 3 of 10 companies on the "Worse" side.
0 other companies' latest entry also says "Restated".
- FY2024RestatedAnnual report
「As COVID-19 is reclassified as a Class 5 infectious disease, we are conducting MR visits in line with the preferences of each medical institution and providing multifaceted information through the effective use of digital promotion to supplement and strengthen our sales capabilities」
Following the reclassification of COVID-19 as a Class 5 infectious disease, we continue our sales activities by combining MR visits with digital promotion. - FY2024-Q3RestatedAnnual report
「As COVID-19 was reclassified as a Category V infectious disease under the Infectious Diseases Control Law, we conducted MR in-person visits in line with the preferences of each medical institution and sought to supplement and strengthen our sales capabilities by providing multifaceted information through the effective use of digital promotion.」
We continue to respond by combining the recovery in medical consultations following the reclassification of COVID-19 as a Class 5 infectious disease with MR visits and digital promotion. - FY2024-Q2MitigatedAnnual report
「As COVID-19 was reclassified as a Category V infectious disease under the Infectious Diseases Control Law, patients' healthcare-seeking behaviour recovered to pre-pandemic levels and」
As COVID-19 was reclassified as a Category V infectious disease, patients' healthcare-seeking behaviour recovered to pre-pandemic levels, easing the previous impact of patients refraining from seeking medical care. - FY2024-Q1MitigatedAnnual report
「As the COVID-19 pandemic entered its winding-down phase, we conducted MR in-person visits in line with the preferences of each medical institution and sought to supplement and strengthen our sales capabilities by providing information through the effective use of digital promotion.」
COVID-19 was considered to be entering its winding-down phase, and the situation shifted to one in which MR in-person visits were conducted. Digital promotion was also used to address the impact on sales activities. - FY2023MitigatedAnnual report
「As patients' healthcare-seeking behaviour returned to normal following the impact of COVID-19, the market grew at a low single-digit rate.」
Although the effects of patients refraining from seeking medical care due to COVID-19 remained, the disclosure noted that patients' healthcare-seeking behaviour was returning to normal and that the market was growing at a low single-digit rate. - FY2023-Q1MitigatedAnnual report
「Although a drug price revision was implemented in April 2022 in line with the basic policies for reform of the drug pricing system, patients' visit patterns were returning to normal after being affected by COVID-19, and the market remained flat.」
Although COVID-19 continued to affect patients' healthcare-seeking behaviour, their behaviour was returning to normal, and the market remained flat, according to the disclosure. - FY2022-Q2RestatedAnnual report
「While the COVID-19 pandemic continued, we refrained from MR in-person visits and other activities in line with the preferences of each medical institution, while seeking to supplement and strengthen our sales capabilities by proactively providing information through the multifaceted use of digital channels in addition to conventional meetings.」
While the effects of patients refraining from seeking medical care and the curtailment of in-person visits due to COVID-19 continued, digital channels were used to supplement sales activities. - FY2022-Q1RestatedAnnual report
「While COVID-19 continued, we conducted MR activities, including refraining from in-person visits, in line with the preferences of each medical institution, and proactively provided information through the multifaceted use of digital channels.」
The effects of refraining from in-person visits and the impact on the market due to COVID-19 have continued. - FY2021-Q3RestatedAnnual report
「The spread of COVID-19 caused the prescription pharmaceutical market to contract as patients refrained from seeking medical care, and delayed market penetration of new drugs as MR activities were curtailed, affecting our business activities as well.」
The effects of the contraction of the market and the curtailment of MR activities due to COVID-19 have continued. - FY2021-Q2RestatedAnnual report
「The spread of COVID-19 caused the prescription pharmaceutical market to contract as patients refrained from seeking medical care, and delayed market penetration of new drugs as MR activities were curtailed, affecting our business activities as well.」
The effects of patients refraining from seeking medical care and the curtailment of MR activities due to COVID-19 have continued and have been reflected in accounting estimates. - FY2021-Q1MaterialisedAnnual report
「During the first quarter of the current consolidated cumulative accounting period, Japan's pharmaceutical market remained in negative growth due to drug price revisions accompanying the consumption tax increase (October 2019, industry average: 2.40%), drug price revisions under the reform of the drug pricing system (April 2020, industry average: 4.38%), and patients refraining from seeking medical care due to the spread of COVID-19.」
COVID-19, whose future impact had been monitored at the end of the previous fiscal year, materialised in the business environment during the current quarter as negative market growth through factors such as patients refraining from seeking medical care. - FY2020First statedAnnual report
「The spread of COVID-19 had no impact on our business, and there was no impact on performance for the consolidated fiscal year. Looking ahead, although the market may contract due to reduced medical consultations, we recognize that this does not currently have a material impact on performance. In light of the potential for further spread of COVID-19, we will closely monitor possible effects on performance from delays in market penetration and product uptake for our new drug portfolio.」
Although no impact on performance was reported for the year, the Group continued to monitor potential future effects from reduced medical consultations and delays in market penetration and product uptake.